Antimullerian Hormone as an Indicator for Ovarian Response

NCT03291860 | Unknown

• 1 other identifier: Antimullerian hormone
• Study Type: observational
• Target: 66
• Locations: 0 countries
• Sites: N/A

Brief Summary

Anti Mullerian hormone (AMH) is gaining place as ovarian marker, chiefly in infertility assistance. Investigators explored its correlation with oocytes retrieval after long GnRH agonist protocol for stimulation, in younger and older infertile population. Methods: This prospective analysis compiled data of 66 females, receiving ICSI treatment from April 2016 to October 2017. Serum FSH, LH, Estadiol, AMH and antral follicle count were assessed. Outcomes were measured as good (5 to 19 oocytes) and bad responders.

Conditions

Infertility, Female

Outcome Measures

Primary Outcomes (1)

• Difference between AMH levels between good and poor responders in young patients receiving long GnRH agonist protocol for ICSI.

  Measurement of AMH level in patients undergoing controlled ovarian stimulation prior to ICSI using long GnRH agonist protocol. Level will be compared between good and poor responders.

  1 month (1 cycle)

Interventions

Ovum retrievum PROCEDURE

assessment of oocytes collected by ovum retrievum to evaluate the discriminatory power of the antimullerian hormone in ICSI cycles

Eligibility Criteria

• Age: 20 Years - 40 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Sixty six women undergoing ICSI were enrolled in and a written informed consent was obtained from each participant

You may qualify if:

• Age:20-40 years old
• BMI:20-40kg/m
• Normal baseline hormonal profile (on the 2nd day of the cycle)
• FSH: 2.5-10.2mlU/ml
• LH:1.9-12.5mlU/ml
• Estradiol (E2): \<50pg/ml
• No Endometriosis by laparoscopy
• No prior ovarian surgery; overectomy, ovariectomy or oophrectomy
• Female subjects who have at least 1 wash-out cycle (defined as greater than or equal to 30 days since the last dose of clomiphene citrate or gonadotrophin treatment) since the last ART cycle and/or clomiphene citrate or gonadotrophin treatment prior to starting gonadotrophin releasing hormone (GnRH) agonist therapy

You may not qualify if:

• \. Age: \<20 or \>40 years old 2. BMI: \<20 or \>40kg/m 3. Female subjects with any contraindication for pregnancy. 4. Female subjects with history of tumors of the hypothalamus \& pituitary gland.
• \. Female subjects with history of ovarian, uterine or mammary cancer. 6. Female subjects with history of hypersensitivity to the active substance of the medications used for ovarian stimulation.
• \. Abnormal baseline hormonal profile 8. Endometriosis by laparoscopy 9. Previous ovarian surgery; overectomy, ovariectomy or oophrectomy 10. Female subjects with abnormal gynecological bleeding of unknown etiology

Sponsors & Collaborators

• Ain Shams Maternity Hospital: lead

MeSH Terms

Conditions

Infertility, Female

Condition Hierarchy (Ancestors)

Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Infertility

Central Study Contacts

Ahmed M Selim, MBBCh

CONTACT

00201123122003; dr.ahmedselim_89@yahoo.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Doctor

Study Record Dates

• First Submitted: September 18, 2017
• First Posted: September 25, 2017
• Study Start: November 10, 2017
• Primary Completion: September 10, 2018
• Study Completion: October 10, 2018
• Last Updated: September 25, 2017

Record last verified: 2017-09